Zoetis options therapeutic antibody from Cellmid; Merck launches veterinarian exchange program;

> Australia's Cellmid signed an option agreement with Zoetis ($ZTS) for one of its MK antibodies, which are being developed for therapeutic use in companion animals. Release

> Merck ($MRK) Animal Health launched the Nobivac Global Vet Exchange Program, which will offer 10 veterinarians the opportunity to visit overseas vet clinics to swap knowledge and expertise. Release

> Jaguar Animal Health named Tim Dotson executive director of regulatory affairs. Dotson previously served in the same position at Sanofi's ($SNY) Merial animal health division. Release

> Zoetis appointed Roman Trawicki president of its global manufacturing and supply group. Trawicki joins from GE Healthcare, where he served as general manager of global supply chain for medical diagnostics. Release

> Newly public Ouro Fino Saúde Animal of Brazil announced that sales in the third quarter rose 10% year over year to R$103.7 million ($39.8 million) and income from continuing operations was R$12 million ($4.6 million), dropping from R$14.6 million during the same period a year ago. Article (reg. req.)

> Investment firm The Rohatyn Group sold 36.6% of its stake in Huvepharma, a Bulgarian developer of animal health products. Release

> Veterinary lab equipment maker Abaxis ($ABAX) acquired the U.K.'s QCR & Trio Diagnostics. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…